
    
      The 12 primary superiority hypotheses will be evaluated by comparing the pembro mono arm or
      pembro combo arm separately to the control arm, for PFS and OS in all first line (1L) R/M
      HNSCC participants and in 1L R/M HNSCC participants with positive PD-L1 expression (PD-L1 CPS
      ≥1 and CPS ≥20).
    
  